- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07863167
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
Studieoversigt
Status
Betingelser
Intervention / Behandling
- Medicin: adebrelimab + SHR-A2009
- Medicin: adebrelimab + SHR-A2009
- Medicin: adebrelimab + SHR-A2009
- Medicin: paclitaxel or pemetrexed combined with carboplatin +adebrelimab
- Medicin: adebrelimab
- Medicin: adebeliizumab + SHR-A2009
- Medicin: adebeliizumab + SHR-A2009
- Medicin: adebeliizumab + platinum-containing double chemotherapy
- Medicin: almonertinib combined with SHR-A2009
- Medicin: almonertinib combined with SHR-A2009
- Medicin: almonertinib
- Medicin: SHR-A2009 combined with almonertinib
- Medicin: almonertinib monotherapy
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Yijing Chen
- Telefonnummer: 0518-82342973
- E-mail: yijing.chen.yc510@hengrui.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Guangdong Provincial People's Hospital
-
Ledende efterforsker:
- Yilong Wu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
- At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
- The ECOG score was 0 or 1.
- Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
- Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
- Participants with active, known or suspected autoimmune diseases.
- Other malignant tumors within 5 years before screening.
- Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
- Participants with severe cardiovascular and cerebrovascular diseases.
- There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
- Arterial and venous thrombosis events occurred within 3 months before the first administration.
- HIV test positive.
- Participants with active hepatitis B or C.
1.Evidence of active tuberculosis infection within 1 year before the first administration.
12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.
14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: group A1-1adebrelimab + SHR-A2009
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab
|
paclitaxel or pemetrexed combined with carboplatin +adebrelimab |
|
Eksperimentel: group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Eksperimentel: group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A2-3 adebrelimab
|
adebrelimab |
|
Eksperimentel: group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Eksperimentel: group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A3-3 adebeliizumab + platinum-containing double chemotherapy
|
adebeliizumab + platinum-containing double chemotherapy |
|
Eksperimentel: group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Eksperimentel: group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group B1-3 almonertinib
|
almonertinib |
|
Eksperimentel: group B2-1 SHR-A2009 combined with almonertinib
|
SHR-A2009 combined with almonertinib |
|
Aktiv komparator: group B2-2 almonertinib monotherapy
|
almonertinib monotherapy |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part A1 : pCR rate;
Tidsramme: about 24 months
|
about 24 months
|
|
Part A2 : 2-year DFS rate;
Tidsramme: about 24 months
|
about 24 months
|
|
Part A3 : pCR rate and 18-month EFS rate;
Tidsramme: about 18 months
|
about 18 months
|
|
Part B1 : 2-year DFS rate.
Tidsramme: about 24 months
|
about 24 months
|
|
Part B2 : MPR rate.
Tidsramme: about 24 months
|
about 24 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The incidence and grade of adverse events;
Tidsramme: about 48 months
|
about 48 months
|
|
surgical complications;
Tidsramme: about 24 months
|
about 24 months
|
|
EFS
Tidsramme: about 24 months ;
|
about 24 months ;
|
|
ORR;
Tidsramme: about 24 months
|
about 24 months
|
|
DFS and DFS rates;
Tidsramme: about 24 months
|
about 24 months
|
|
OS ;
Tidsramme: about 48 months
|
about 48 months
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Karcinom, ikke-småcellet lunge
- Organiske kemikalier
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Taxoider
- Cyclodecanes
- Diterpenes
- Paclitaxel
- Aumolertinib
Andre undersøgelses-id-numre
- SHR-A2009-203
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .